Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Monoclonal Antibodies in Veterinary Health Market

ID: MRFR/HC/40355-HCR
200 Pages
Rahul Gotadki
Last Updated: April 24, 2026

Global Monoclonal Antibodies in Veterinary Health Market Research Report: Size, Share, Trend Analysis By Applications (Infectious Diseases, Autoimmune Disorders, Cancer Treatments, Pain Management), By Animal Type (Cats, Dogs, Horses, Livestock, Fish), By Source (Murine, Chimeric, Humanized, Fully Human), By Route of Administration (Intravenous, Subcutaneous, Intramuscular) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Monoclonal Antibodies in Veterinary Health Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Infectious Diseases
  50.     4.1.2 Autoimmune Disorders
  51.     4.1.3 Cancer Treatments
  52.     4.1.4 Pain Management
  53.   4.2 Healthcare, BY Animal Type (USD Billion)
  54.     4.2.1 Cats
  55.     4.2.2 Dogs
  56.     4.2.3 Horses
  57.     4.2.4 Livestock
  58.     4.2.5 Fish
  59.   4.3 Healthcare, BY Source (USD Billion)
  60.     4.3.1 Murine
  61.     4.3.2 Chimeric
  62.     4.3.3 Humanized
  63.     4.3.4 Fully Human
  64.   4.4 Healthcare, BY Route of Administration (USD Billion)
  65.     4.4.1 Intravenous
  66.     4.4.2 Subcutaneous
  67.     4.4.3 Intramuscular
  68.   4.5 Healthcare, BY Region (USD Billion)
  69.     4.5.1 North America
  70.       4.5.1.1 US
  71.       4.5.1.2 Canada
  72.     4.5.2 Europe
  73.       4.5.2.1 Germany
  74.       4.5.2.2 UK
  75.       4.5.2.3 France
  76.       4.5.2.4 Russia
  77.       4.5.2.5 Italy
  78.       4.5.2.6 Spain
  79.       4.5.2.7 Rest of Europe
  80.     4.5.3 APAC
  81.       4.5.3.1 China
  82.       4.5.3.2 India
  83.       4.5.3.3 Japan
  84.       4.5.3.4 South Korea
  85.       4.5.3.5 Malaysia
  86.       4.5.3.6 Thailand
  87.       4.5.3.7 Indonesia
  88.       4.5.3.8 Rest of APAC
  89.     4.5.4 South America
  90.       4.5.4.1 Brazil
  91.       4.5.4.2 Mexico
  92.       4.5.4.3 Argentina
  93.       4.5.4.4 Rest of South America
  94.     4.5.5 MEA
  95.       4.5.5.1 GCC Countries
  96.       4.5.5.2 South Africa
  97.       4.5.5.3 Rest of MEA
  98. 5 SECTION V: COMPETITIVE ANALYSIS
  99.   5.1 Competitive Landscape
  100.     5.1.1 Overview
  101.     5.1.2 Competitive Analysis
  102.     5.1.3 Market share Analysis
  103.     5.1.4 Major Growth Strategy in the Healthcare
  104.     5.1.5 Competitive Benchmarking
  105.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  106.     5.1.7 Key developments and growth strategies
  107.       5.1.7.1 New Product Launch/Service Deployment
  108.       5.1.7.2 Merger & Acquisitions
  109.       5.1.7.3 Joint Ventures
  110.     5.1.8 Major Players Financial Matrix
  111.       5.1.8.1 Sales and Operating Income
  112.       5.1.8.2 Major Players R&D Expenditure. 2023
  113.   5.2 Company Profiles
  114.     5.2.1 Zoetis (US)
  115.       5.2.1.1 Financial Overview
  116.       5.2.1.2 Products Offered
  117.       5.2.1.3 Key Developments
  118.       5.2.1.4 SWOT Analysis
  119.       5.2.1.5 Key Strategies
  120.     5.2.2 Boehringer Ingelheim (DE)
  121.       5.2.2.1 Financial Overview
  122.       5.2.2.2 Products Offered
  123.       5.2.2.3 Key Developments
  124.       5.2.2.4 SWOT Analysis
  125.       5.2.2.5 Key Strategies
  126.     5.2.3 Merck Animal Health (US)
  127.       5.2.3.1 Financial Overview
  128.       5.2.3.2 Products Offered
  129.       5.2.3.3 Key Developments
  130.       5.2.3.4 SWOT Analysis
  131.       5.2.3.5 Key Strategies
  132.     5.2.4 Elanco Animal Health (US)
  133.       5.2.4.1 Financial Overview
  134.       5.2.4.2 Products Offered
  135.       5.2.4.3 Key Developments
  136.       5.2.4.4 SWOT Analysis
  137.       5.2.4.5 Key Strategies
  138.     5.2.5 Virbac (FR)
  139.       5.2.5.1 Financial Overview
  140.       5.2.5.2 Products Offered
  141.       5.2.5.3 Key Developments
  142.       5.2.5.4 SWOT Analysis
  143.       5.2.5.5 Key Strategies
  144.     5.2.6 Ceva Santé Animale (FR)
  145.       5.2.6.1 Financial Overview
  146.       5.2.6.2 Products Offered
  147.       5.2.6.3 Key Developments
  148.       5.2.6.4 SWOT Analysis
  149.       5.2.6.5 Key Strategies
  150.     5.2.7 Merial (now part of Boehringer Ingelheim) (US)
  151.       5.2.7.1 Financial Overview
  152.       5.2.7.2 Products Offered
  153.       5.2.7.3 Key Developments
  154.       5.2.7.4 SWOT Analysis
  155.       5.2.7.5 Key Strategies
  156.     5.2.8 Abaxis (US)
  157.       5.2.8.1 Financial Overview
  158.       5.2.8.2 Products Offered
  159.       5.2.8.3 Key Developments
  160.       5.2.8.4 SWOT Analysis
  161.       5.2.8.5 Key Strategies
  162.   5.3 Appendix
  163.     5.3.1 References
  164.     5.3.2 Related Reports
  165. 6 LIST OF FIGURES
  166.   6.1 MARKET SYNOPSIS
  167.   6.2 NORTH AMERICA MARKET ANALYSIS
  168.   6.3 US MARKET ANALYSIS BY APPLICATION
  169.   6.4 US MARKET ANALYSIS BY ANIMAL TYPE
  170.   6.5 US MARKET ANALYSIS BY SOURCE
  171.   6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  172.   6.7 CANADA MARKET ANALYSIS BY APPLICATION
  173.   6.8 CANADA MARKET ANALYSIS BY ANIMAL TYPE
  174.   6.9 CANADA MARKET ANALYSIS BY SOURCE
  175.   6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  176.   6.11 EUROPE MARKET ANALYSIS
  177.   6.12 GERMANY MARKET ANALYSIS BY APPLICATION
  178.   6.13 GERMANY MARKET ANALYSIS BY ANIMAL TYPE
  179.   6.14 GERMANY MARKET ANALYSIS BY SOURCE
  180.   6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  181.   6.16 UK MARKET ANALYSIS BY APPLICATION
  182.   6.17 UK MARKET ANALYSIS BY ANIMAL TYPE
  183.   6.18 UK MARKET ANALYSIS BY SOURCE
  184.   6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  185.   6.20 FRANCE MARKET ANALYSIS BY APPLICATION
  186.   6.21 FRANCE MARKET ANALYSIS BY ANIMAL TYPE
  187.   6.22 FRANCE MARKET ANALYSIS BY SOURCE
  188.   6.23 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  189.   6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
  190.   6.25 RUSSIA MARKET ANALYSIS BY ANIMAL TYPE
  191.   6.26 RUSSIA MARKET ANALYSIS BY SOURCE
  192.   6.27 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  193.   6.28 ITALY MARKET ANALYSIS BY APPLICATION
  194.   6.29 ITALY MARKET ANALYSIS BY ANIMAL TYPE
  195.   6.30 ITALY MARKET ANALYSIS BY SOURCE
  196.   6.31 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  197.   6.32 SPAIN MARKET ANALYSIS BY APPLICATION
  198.   6.33 SPAIN MARKET ANALYSIS BY ANIMAL TYPE
  199.   6.34 SPAIN MARKET ANALYSIS BY SOURCE
  200.   6.35 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  201.   6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
  202.   6.37 REST OF EUROPE MARKET ANALYSIS BY ANIMAL TYPE
  203.   6.38 REST OF EUROPE MARKET ANALYSIS BY SOURCE
  204.   6.39 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  205.   6.40 APAC MARKET ANALYSIS
  206.   6.41 CHINA MARKET ANALYSIS BY APPLICATION
  207.   6.42 CHINA MARKET ANALYSIS BY ANIMAL TYPE
  208.   6.43 CHINA MARKET ANALYSIS BY SOURCE
  209.   6.44 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  210.   6.45 INDIA MARKET ANALYSIS BY APPLICATION
  211.   6.46 INDIA MARKET ANALYSIS BY ANIMAL TYPE
  212.   6.47 INDIA MARKET ANALYSIS BY SOURCE
  213.   6.48 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  214.   6.49 JAPAN MARKET ANALYSIS BY APPLICATION
  215.   6.50 JAPAN MARKET ANALYSIS BY ANIMAL TYPE
  216.   6.51 JAPAN MARKET ANALYSIS BY SOURCE
  217.   6.52 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  218.   6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
  219.   6.54 SOUTH KOREA MARKET ANALYSIS BY ANIMAL TYPE
  220.   6.55 SOUTH KOREA MARKET ANALYSIS BY SOURCE
  221.   6.56 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  222.   6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
  223.   6.58 MALAYSIA MARKET ANALYSIS BY ANIMAL TYPE
  224.   6.59 MALAYSIA MARKET ANALYSIS BY SOURCE
  225.   6.60 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  226.   6.61 THAILAND MARKET ANALYSIS BY APPLICATION
  227.   6.62 THAILAND MARKET ANALYSIS BY ANIMAL TYPE
  228.   6.63 THAILAND MARKET ANALYSIS BY SOURCE
  229.   6.64 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  230.   6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
  231.   6.66 INDONESIA MARKET ANALYSIS BY ANIMAL TYPE
  232.   6.67 INDONESIA MARKET ANALYSIS BY SOURCE
  233.   6.68 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  234.   6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
  235.   6.70 REST OF APAC MARKET ANALYSIS BY ANIMAL TYPE
  236.   6.71 REST OF APAC MARKET ANALYSIS BY SOURCE
  237.   6.72 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  238.   6.73 SOUTH AMERICA MARKET ANALYSIS
  239.   6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
  240.   6.75 BRAZIL MARKET ANALYSIS BY ANIMAL TYPE
  241.   6.76 BRAZIL MARKET ANALYSIS BY SOURCE
  242.   6.77 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  243.   6.78 MEXICO MARKET ANALYSIS BY APPLICATION
  244.   6.79 MEXICO MARKET ANALYSIS BY ANIMAL TYPE
  245.   6.80 MEXICO MARKET ANALYSIS BY SOURCE
  246.   6.81 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  247.   6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
  248.   6.83 ARGENTINA MARKET ANALYSIS BY ANIMAL TYPE
  249.   6.84 ARGENTINA MARKET ANALYSIS BY SOURCE
  250.   6.85 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  251.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  252.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ANIMAL TYPE
  253.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY SOURCE
  254.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  255.   6.90 MEA MARKET ANALYSIS
  256.   6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
  257.   6.92 GCC COUNTRIES MARKET ANALYSIS BY ANIMAL TYPE
  258.   6.93 GCC COUNTRIES MARKET ANALYSIS BY SOURCE
  259.   6.94 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  260.   6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
  261.   6.96 SOUTH AFRICA MARKET ANALYSIS BY ANIMAL TYPE
  262.   6.97 SOUTH AFRICA MARKET ANALYSIS BY SOURCE
  263.   6.98 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  264.   6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
  265.   6.100 REST OF MEA MARKET ANALYSIS BY ANIMAL TYPE
  266.   6.101 REST OF MEA MARKET ANALYSIS BY SOURCE
  267.   6.102 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  268.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  269.   6.104 RESEARCH PROCESS OF MRFR
  270.   6.105 DRO ANALYSIS OF HEALTHCARE
  271.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  272.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  273.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  274.   6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  275.   6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  276.   6.111 HEALTHCARE, BY ANIMAL TYPE, 2024 (% SHARE)
  277.   6.112 HEALTHCARE, BY ANIMAL TYPE, 2024 TO 2035 (USD Billion)
  278.   6.113 HEALTHCARE, BY SOURCE, 2024 (% SHARE)
  279.   6.114 HEALTHCARE, BY SOURCE, 2024 TO 2035 (USD Billion)
  280.   6.115 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  281.   6.116 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  282.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  283. 7 LIST OF TABLES
  284.   7.1 LIST OF ASSUMPTIONS
  285.     7.1.1
  286.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  287.     7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  288.     7.2.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  289.     7.2.3 BY SOURCE, 2025-2035 (USD Billion)
  290.     7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  291.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  292.     7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
  293.     7.3.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  294.     7.3.3 BY SOURCE, 2025-2035 (USD Billion)
  295.     7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  296.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  297.     7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
  298.     7.4.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  299.     7.4.3 BY SOURCE, 2025-2035 (USD Billion)
  300.     7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  301.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  302.     7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
  303.     7.5.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  304.     7.5.3 BY SOURCE, 2025-2035 (USD Billion)
  305.     7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  306.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  307.     7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
  308.     7.6.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  309.     7.6.3 BY SOURCE, 2025-2035 (USD Billion)
  310.     7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  311.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  312.     7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
  313.     7.7.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  314.     7.7.3 BY SOURCE, 2025-2035 (USD Billion)
  315.     7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  316.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  317.     7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
  318.     7.8.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  319.     7.8.3 BY SOURCE, 2025-2035 (USD Billion)
  320.     7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  321.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  322.     7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
  323.     7.9.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  324.     7.9.3 BY SOURCE, 2025-2035 (USD Billion)
  325.     7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  326.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  327.     7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
  328.     7.10.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  329.     7.10.3 BY SOURCE, 2025-2035 (USD Billion)
  330.     7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  331.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  332.     7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
  333.     7.11.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  334.     7.11.3 BY SOURCE, 2025-2035 (USD Billion)
  335.     7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  336.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  337.     7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
  338.     7.12.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  339.     7.12.3 BY SOURCE, 2025-2035 (USD Billion)
  340.     7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  341.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  342.     7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
  343.     7.13.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  344.     7.13.3 BY SOURCE, 2025-2035 (USD Billion)
  345.     7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  346.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  347.     7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
  348.     7.14.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  349.     7.14.3 BY SOURCE, 2025-2035 (USD Billion)
  350.     7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  351.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  352.     7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
  353.     7.15.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  354.     7.15.3 BY SOURCE, 2025-2035 (USD Billion)
  355.     7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  356.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  357.     7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
  358.     7.16.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  359.     7.16.3 BY SOURCE, 2025-2035 (USD Billion)
  360.     7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  361.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  362.     7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
  363.     7.17.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  364.     7.17.3 BY SOURCE, 2025-2035 (USD Billion)
  365.     7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  366.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  367.     7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
  368.     7.18.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  369.     7.18.3 BY SOURCE, 2025-2035 (USD Billion)
  370.     7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  371.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  372.     7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
  373.     7.19.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  374.     7.19.3 BY SOURCE, 2025-2035 (USD Billion)
  375.     7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  376.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  377.     7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
  378.     7.20.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  379.     7.20.3 BY SOURCE, 2025-2035 (USD Billion)
  380.     7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  381.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  382.     7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
  383.     7.21.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  384.     7.21.3 BY SOURCE, 2025-2035 (USD Billion)
  385.     7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  386.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  387.     7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
  388.     7.22.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  389.     7.22.3 BY SOURCE, 2025-2035 (USD Billion)
  390.     7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  391.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  392.     7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
  393.     7.23.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  394.     7.23.3 BY SOURCE, 2025-2035 (USD Billion)
  395.     7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  396.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  397.     7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
  398.     7.24.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  399.     7.24.3 BY SOURCE, 2025-2035 (USD Billion)
  400.     7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  401.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  402.     7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
  403.     7.25.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  404.     7.25.3 BY SOURCE, 2025-2035 (USD Billion)
  405.     7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  406.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  407.     7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
  408.     7.26.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  409.     7.26.3 BY SOURCE, 2025-2035 (USD Billion)
  410.     7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  411.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  412.     7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
  413.     7.27.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  414.     7.27.3 BY SOURCE, 2025-2035 (USD Billion)
  415.     7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  416.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  417.     7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
  418.     7.28.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  419.     7.28.3 BY SOURCE, 2025-2035 (USD Billion)
  420.     7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  421.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  422.     7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
  423.     7.29.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  424.     7.29.3 BY SOURCE, 2025-2035 (USD Billion)
  425.     7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  426.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  427.     7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
  428.     7.30.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
  429.     7.30.3 BY SOURCE, 2025-2035 (USD Billion)
  430.     7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  431.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  432.     7.31.1
  433.   7.32 ACQUISITION/PARTNERSHIP
  434.     7.32.1

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Infectious Diseases
  • Autoimmune Disorders
  • Cancer Treatments
  • Pain Management

Healthcare By Animal Type (USD Billion, 2025-2035)

  • Cats
  • Dogs
  • Horses
  • Livestock
  • Fish

Healthcare By Source (USD Billion, 2025-2035)

  • Murine
  • Chimeric
  • Humanized
  • Fully Human

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Intramuscular

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions